Leading biotechnology company Shantha Biotech said on Friday that it has developed recombinant interferon technology for cancer and viral hepatitis patients for which it is seeking a patent.
'Shanferon', a recombinant interferon is used for patients suffering from chronic myeloid leukemia, chronic viral hepatitis and other cancers, a company release said.
Shantha has applied for patent in the US and Europe.
It has recently received an award from the Union Government for developing and commercially marketing this technology, it added.